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        Nearly all cells in jawed vertebrates con-
stitutively express surface major histo-
compatibility complex (MHC) class I 
molecules. Upon infection with viruses 
and intracellular pathogens, class I mol-
ecules present oligopeptides derived from 
pathogen gene products for recognition 
by CD8 
   T cells. The generation of 
antigenic peptides typically begins in 
the cytosol where proteasomes gener-
ate antigenic peptide precursors with 
amino terminal extensions. These pre-
cursors are then trimmed by peptidases 
before and/or after peptide transport 
into the endoplasmic reticulum (ER) 
by transporter associated with antigen 
processing. Peptides that bind with high 
affi   nity to class I molecules trigger the 
release of the peptide–class I complex 
from the ER. These complexes are dis-
played at the cell surface for perusal by 
CD8 
   T cells in virus-infected tissues. 
A key question in class I antigen pro-
cessing is which source(s) of proteasome 
substrates gives rise to class I peptide 
ligands. Although DRiPs arising from 
polypeptides translated in-frame are well 
documented as a source of class I  –  bind-
ing peptides, a new study by Maness et al. 
in this issue (p.     25    0    5    ; reference   1  ) shows 
that DRiPs derived from ARFs can 
CD8 
   T cells rapidly recognize virus-infected cells due to the generation of 
antigenic peptides from defective ribosomal products (DRiPs) that are en-
coded by standard open reading frames (ORFs). New data now show that 
alternative reading frame (ARF) DRiPs can also induce robust CD8 
   T cell 
responses. ARF-specifi  c T cells control retroviral replication and select for 
viral escape in monkeys, providing the most compelling evidence to date for 
the biological relevance of ARF immunosurveillance.
  J.W. Yewdell and H.D. Hickman are at Laboratory 
of Viral Diseases, National Institute of Allergy and 
Infectious Diseases, Bethesda, MD 20892. 
 CORRESPONDENCE   
 J.W.Y.:  jyewdell@nih.gov 
  New lane in the information highway: alternative 
reading frame peptides elicit T cells with potent 
antiretrovirus activity 
  Jonathan W. Yewdell and Heather D. Hickman   
also induce highly eff  ective antiviral T 
cell immunity. 
  Rethinking immunosurveillance 
  Key insights into biological systems can 
be gleaned by considering their evolu-
tion. The MHC class I antigen process-
ing system is generally believed to have 
evolved as a result of selective pressures 
imposed by intracellular pathogens. New 
fi  ndings, however, have resurrected the 
idea that cancer immuno  surveillance, a 
process that seeks and destroys cancers 
of nonviral origin, was a key factor in 
the evolution of the class I  –  CD8 
   T cell 
system. Remarkably, lethal tumors can 
be transmitted in two mammalian species 
by direct transfer of tumor cells them-
selves and not by tumor viruses, as was 
generally assumed (  2, 3  ). The need to 
reject such transmissible tumors may 
have provided a strong selective pressure 
in the evolution of immunosurveillance. 
Indeed, the constitutive expression of 
class I molecules (as opposed to their in-
duction by infection) may have evolved 
primarily to facilitate the detection of 
transmissible and spontaneously arising 
tumors (  4  ). 
  Detection of these tumors would be 
most effi   cient if active gene expression 
was monitored independently of mRNA 
abundance and protein stability. This 
would prevent the overloading of class I 
molecules with peptides from the most 
abundant cellular proteins (structural 
elements, chaperones, ribosomes, etc.), 
which are rarely altered in neoplasms. 
Indeed, analysis of the class I immuno-
peptidome reveals little correlation be-
tween the abundance of mRNAs and 
class I  –  binding peptides (  5, 6  ). Rather, 
these peptides appear to be selected for 
presentation by some other metric that 
favors rare mRNA species and peptides 
from gene products translated by non-
standard rules (  7  ), perhaps by a subset of 
ribosomes ( “  immunoribosomes  ”  ) whose 
products have privileged access to the 
class I processing pathway (  8, 9  ). 
  The possible evolution of this path-
way for detecting peptides from tumor 
cell gene products that are rare or are 
rapidly degraded may have infl  uenced 
the mechanisms used to monitor viral 
gene expression. Studies in a variety of 
systems point to an intimate kinetic 
link between protein synthesis and the 
genera  tion of viral and cellular pep-
tides that bind to class I MHC ( 8  ). This 
is expected for nonstandard gene pro-
ducts (ARFs, downstream or alter native 
initiation, stop codon read through), 
which misfold and are rapidly targeted 
for degradation. Surprisingly, however, 
this also applies to peptides derived from 
standard viral and cellular ORFs (  10  ). 
Rapid degradation may result from un-
avoidable mistakes in transcription, trans-
lation, protein folding, or assembly of 
multi-subunit proteins. Alternatively, 
immunoribosomes (should they exist) 
may directly target their translation pro-
ducts for rapid degradation to enable 
immunosurveillance. 
  Together, the various forms of rap-
idly degraded polypeptides are termed 
DRiPs. Surveillance of DRiPs may have 
evolved to facilitate tumor cell recogni-
tion. But this surveillance may also en-
able the immune system to rapidly detect 
viral infections by monitoring what is 
actively being translated, rather than 2502 ARF IMMUNOSURVEILLANCE | Yewdell and Hickman
with high affi   nity (K  d    32 nM), and 
SIV-infected Mamu-B*17 
   macaques 
mount a strong B*17-restricted CD8 
   T 
cell response against this peptide. 
  The biological relevance of this re-
sponse was elegantly evinced by two 
fi  ndings. First, CD8 
   T cells specifi  c for 
the peptide inhibited replication of virus 
in vitro in B*17-expressing cells. Second, 
and most remarkably, 5 of 20 B*17 
   
SIV-infected animals selected for viral 
escape mutants with the identical point 
mutation, which recodes the C-terminal 
anchor residue of the peptide from W to 
K (and is synonymous in Env). This 
substitution caused a 30-fold reduction 
in the binding of the mutant peptide to 
B*17 and prevented peptide-specifi  c 
CD8 
   T cells from recognizing cells in-
fected with the escape mutant. As the 
fi  rst report of an ARF-encoded deter-
minant that facilitates viral evolution in 
response to immune pressure, these fi  nd-
ings provide the smoking gun for the in 
vivo relevance of ARFPs. 
  The list of bona fi  de viral ARFPs 
is short. This undoubtedly refl  ects, in 
part, investigator bias in searching for 
immuno  genic determinants in only the 
most obvious places. It is now possible 
to predict in silico high affi   nity class I  – 
binding peptides with an accuracy as high 
as 90% (  21  ). The success of Maness et al. 
in using this approach should spur in-
vestigators to systematically search for 
ARFPs in other viruses. Moreover, as 
improvements in mass spectroscopy 
enable more rapid and sensitive identi-
fi  cation of peptides recovered from MHC 
class I molecules, spectroscopists should 
compare detected masses with all six 
possible reading frames for potential 
matches and not forget about nucleic acid 
or direct proteasome-mediated peptide 
splicing, which can even reorder pep-
tide sequences (  22  ). 
  Alternative peptides recognized by 
virus-induced CD8 
   T cells may also 
be encoded by the host. The initial study 
that characterized HIV class I peptide 
ligands using mass spectroscopy identi-
fi  ed three peptides that were not present 
on uninfected cells (  23  ). Remarkably, 
however, each of these peptides was 
encoded by the human vinculin gene, 
whose expression is enhanced by HIV 
pseudo-ARF. The fi  rst viral ARF that was 
reported to have CD8 
   T cell immuno-
genicity is probably also an ORF with 
an important function in viral patho-
genesis (  14  ). Similarly, immunogenic 
ARFs from the hepatitis C virus, which 
elicit CD4 
   T cell and antibody re-
sponses (  15  ), now have ascribed func-
tions (  16  ), bestowing ORFhood on these 
gene products. 
  ARFs created by genetic manipula-
tion of viral (  17, 18  ) or plasmid ORFs 
(  19  ) have also been shown to demon-
strate antigenicity and immunogenicity. 
Several immunogenic ARFPs have been 
reported for tumor antigens (  11  ), but it 
is difficult to establish that their ex-
pression (and immunogenicity) is not 
based on legitimate splicing events that 
only occur in vivo. The best case for 
natural ARFPs comes from studies of 
immunodefi  ciency viruses. In a seminal 
study, Cardinaud et al. (  20  ) described 
six ARFPs encoded by human immuno-
defi  ciency virus (HIV) and provided 
evidence for their immunogenicity in 
humans. These six peptides were encoded 
by three ARFs ranging from 33 to 52 
residues, which is much shorter than is 
typically needed to generate a stably 
folded, functional protein. There is also 
no evidence that these gene products are 
functional. Although it is impossible to 
prove the lack of function of an ARF 
gene product, documenting that a trans-
lated gene product is rapidly degraded is 
a good start (though perversely, a sizable 
fraction of PB1-F2 is rapidly degraded; 
reference   12  ). 
  ARFs as sources of biologically 
important determinants 
  In this issue, Maness et al. (  1  ) use the 
Rhesus macaque simian immunodefi  -
ciency virus (SIV) model to establish the 
in vivo relevance of viral ARFPs. Us-
ing computer algorithms to predict SIV 
ARFPs with high affi   nity for the Mamu 
B*17 class I molecule, they identifi  ed 
a potential immunogenic peptide. This 
peptide originates from an ARF of the 
viral Env protein (or the incompletely 
spliced product of the viral protein Rev, 
as these genes occupy overlapping reading 
frames). A synthetic version of the pep-
tide, they show, binds to class I molecules 
what has already been translated. Viral 
proteins are typically highly stable (half-
life in days, not minutes). Antigenic pep-
tides are thus unlikely to be derived from 
the standard turnover of these proteins, 
as it would take many hours to generate 
enough peptides from even the most 
abundant viral proteins to compete with 
those generated from the billions of cel-
lular proteins present at the time of in-
fection. Additionally, using DRiPs as a 
source of peptides provides a mechanism 
for monitoring the expression of     25% 
of cellular gene products (and many vi-
ral proteins) that are targeted to the ER 
for secretion or cell surface display, and 
that are eventually degraded by extra-
cytosolic proteases. 
  ARF or ORF? 
  Although most cellular and viral pep-
tide ligands appear to arise from DRiPs 
encoded by standard reading frames, 
increasing numbers of ARF-encoded 
peptides (ARFPs) have been reported 
(  11  ). An   “  ARF  ”   is simply defi  ned as an 
overlapping reading frame that does not 
encode a functional gene product. But 
extreme caution must be exercised when 
applying this label to uncharacterized 
gene products. Although some ARFs are 
synthesized as errors in translation (and 
are thus DRiPs), proteins encoded by 
overlapping reading frames can be func-
tional products of natural selection. Many 
viruses, especially those with small ge-
nomes, use overlapping reading frames 
and/or multiple splice sites to create 
functional viral proteins. The infl  uenza 
A virus protein, PB1-F2, is the poster 
child for ARFs that are really ORFs. 
This 87-residue protein was serendipi-
tously discovered in the fi  rst systematic 
survey for viral ARFPs and was identi-
fi  ed as the source of a highly immuno-
genic peptide in infl  uenza virus  –  infected 
B6 mice (  12  ). 
  PB1-F2 is encoded by the 1 read-
ing frame of the PB1 polymerase genes 
in     90% of human and avian infl  uenza 
viruses. PB1-F2 is an abundantly syn-
thesized mitochondrial protein that plays 
an important role in viral pathogenesis 
(  13  ). Had PB1-F2 been discovered be-
fore PB1, it would have been consid-
ered the ORF, and PB1 the (very long) JEM VOL. 204, October 29, 2007  2503
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pressure to maintain its function. An ef-
fective CD8 
   T cell response, there-
fore, will result in rapid mutation of the 
targeted peptides, particularly in RNA 
viruses, which have extremely high mu-
tation rates. It is important to note that 
this argument is much less relevant for 
tumor ARFPs, as tumor-specifi  c deter-
minants are both more diffi   cult to iden-
tify and much more genetically stable than 
viral determinants. 
  But doubts about practical uses for 
viral ARFPs should in no way dampen 
enthusiasm for their further discovery 
and characterization. Understanding im-
munity to viruses requires the charac-
terization of the full breadth of the 
immune response to viral peptides and, 
as Maness et al. demonstrate, ARFPs 
can be crucial in controlling viral repli-
cation and in driving viral evolution. 
Moreover, understanding the mecha-
nisms for ARFP generation will no 
doubt provide unique insights into the 
varied processes by which the informa-
tion encoded by nucleic acids is con-
verted into polypeptides. Time and time 
again, such curiosity-driven explorations 
into basic cell biology have generated 
practical applications in diverse areas 
that extend beyond the immediate topic 
of interest. 
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   
T cells obtained from several HIV-in-
fected individuals, but not from uninfected 
hosts, recognized these self-determinants. 
Similarly, measles virus infection induces 
human autoreactive CD8 
   T cells that 
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The latest mass spectrometric sequencing 
study of HIV-induced class I peptide 
ligands identifi  ed no fewer than 15 host-
derived peptides that were absent in 
uninfected cells (  25  ). Although acute 
viral infections are frequently suspected 
of initiating chronic auto immune diseases 
(with little supporting evidence to date), 
these fi  ndings raise the important but 
frequently overlooked question regard-
ing the extent to which self-limited au-
toreactive CD8 
   T cells might contribute 
to antiviral responses. 
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   T cell responses, regardless of 
their physiological function, is too dan-
gerous to be considered in vaccine de-
sign. But what about viral ARFPs? In 
theory, the most eff  ective CD8 
   T cell  – 
based vaccines should encompass the 
widest possible range of viral peptides 
that are naturally displayed by class I 
molecules on infected cells. Maness et al. 
clearly demonstrate that ARF-derived 
peptides can generate robust, highly pro-
tective responses. It is possible to design 
vaccines that deliberately (over)express 
all possible reading frames of viral pro-
teins, even targeting them for rapid 
degradation in vectors designed for di-
rect priming. 
  Unless further research demonstrates 
the ubiquitous targeting of viral ARFPs 
by CD8 
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counterproductive. Moreover, the fi  nd-
ings of Maness et al. uncover the Achil-
les heel of ARFPs: if the source ARFP 
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